{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:24:15Z","timestamp":1794281055018,"version":"4.9.0"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Although doxorubicin chemotherapy is commonly applied for treating different malignant tumors, cardiotoxicity induced by this chemotherapeutic agent restricts its clinical use. The use of silymarin\/silibinin may mitigate the doxorubicin-induced cardiac adverse effects. For this aim, the potential cardioprotective effects of silymarin\/silibinin against the doxorubicin-induced cardiotoxicity were systematically reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we performed a systematic search in accordance with PRISMA guideline for identifying all relevant studies on \u201cthe role of silymarin\/silibinin against doxorubicin-induced cardiotoxicity\u201d in different electronic databases up to June 2022. Sixty-one articles were obtained and screened based on the predefined inclusion and exclusion criteria. Thirteen eligible papers were finally included in this review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>According to the echocardiographic and electrocardiographic findings, the doxorubicin-treated groups presented a significant reduction in ejection fraction, tissue Doppler peak mitral annulus systolic velocity, and fractional shortening as well as bradycardia, prolongation of QT and QRS interval. However, these echocardiographic abnormalities were obviously improved in the silymarin plus doxorubicin groups. As well, the doxorubicin administration led to induce histopathological and biochemical changes in the cardiac cells\/tissue; in contrast, the silymarin\/silibinin co-administration could mitigate these induced alterations (for most of the cases).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>According to the findings, it was found that the co-administration of silymarin\/silibinin alleviates the doxorubicin-induced cardiac adverse effects. Silymarin\/silibinin exerts its cardioprotective effects via antioxidant, anti-inflammatory, anti-apoptotic activities, and other mechanisms.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12935-023-02936-4","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T16:03:28Z","timestamp":1683734608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A systematic review of the protective effects of silymarin\/silibinin against doxorubicin-induced cardiotoxicity"],"prefix":"10.1186","volume":"23","author":[{"given":"Mandeep","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa M.","family":"Kadhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abduladheem","family":"Turki Jalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamam Kareem","family":"Oudah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zafar","family":"Aminov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alsaikhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanko Hassan","family":"Jawhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s Alexis","family":"Ram\u00edrez-Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagher","family":"Farhood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,10]]},"reference":[{"key":"2936_CR1","doi-asserted-by":"publisher","first-page":"119020","DOI":"10.1016\/j.lfs.2021.119020","volume":"269","author":"K Mortezaee","year":"2021","unstructured":"Mortezaee K, Narmani A, Salehi M, Bagheri H, Farhood B, Haghi-Aminjan H, Najafi M. Synergic effects of nanoparticles-mediated hyperthermia in radiotherapy\/chemotherapy of cancer. Life Sci. 2021;269:119020.","journal-title":"Life Sci"},{"key":"2936_CR2","doi-asserted-by":"publisher","first-page":"107741","DOI":"10.1016\/j.intimp.2021.107741","volume":"96","author":"S Sheikholeslami","year":"2021","unstructured":"Sheikholeslami S, Khodaverdian S, Dorri-Giv M, Mohammad Hosseini S, Souri S, Abedi-Firouzjah R, Zamani H, Dastranj L, Farhood B. The radioprotective effects of alpha-lipoic acid on radiotherapy-induced toxicities: a systematic review. Int Immunopharmacol. 2021;96:107741.","journal-title":"Int Immunopharmacol"},{"key":"2936_CR3","doi-asserted-by":"publisher","first-page":"119721","DOI":"10.1016\/j.lfs.2021.119721","volume":"281","author":"S Sheikholeslami","year":"2021","unstructured":"Sheikholeslami S, Aryafar T, Abedi-Firouzjah R, Banaei A, Dorri-Giv M, Zamani H, Ataei G, Majdaeen M, Farhood B. The role of melatonin on radiation-induced pneumonitis and lung fibrosis: a systematic review. Life Sci. 2021;281:119721.","journal-title":"Life Sci"},{"issue":"sup3","key":"2936_CR4","doi-asserted-by":"publisher","first-page":"S1215","DOI":"10.1080\/21691401.2018.1536062","volume":"46","author":"N Abdi Goushbolagh","year":"2018","unstructured":"Abdi Goushbolagh N, Abedi Firouzjah R, Ebrahimnejad Gorji K, Khosravanipour M, Moradi S, Banaei A, Astani A, Najafi M, Zare MH, Farhood B. Estimation of radiation dose-reduction factor for cerium oxide nanoparticles in MRC-5 human lung fibroblastic cells and MCF-7 breast-cancer cells. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S1215-s1225.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"2936_CR5","doi-asserted-by":"publisher","first-page":"106761","DOI":"10.1016\/j.intimp.2020.106761","volume":"86","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Najafi M. Damage-associated molecular patterns in tumor radiotherapy. Int Immunopharmacol. 2020;86:106761.","journal-title":"Int Immunopharmacol"},{"key":"2936_CR6","doi-asserted-by":"publisher","first-page":"106663","DOI":"10.1016\/j.intimp.2020.106663","volume":"85","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Rezaeyan A, Najafi M. Abscopal effect in radioimmunotherapy. Int Immunopharmacol. 2020;85:106663.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2936_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1051\/bmdcn\/2017070423","volume":"7","author":"CY Huang","year":"2017","unstructured":"Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine. 2017;7(4):23.","journal-title":"Biomedicine"},{"key":"2936_CR8","doi-asserted-by":"crossref","unstructured":"Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA A Cancer J Clin. 2019; 69(5):363\u201385.","DOI":"10.3322\/caac.21565"},{"issue":"4","key":"2936_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","volume":"1","author":"C Fitzmaurice","year":"2015","unstructured":"Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505\u201327.","journal-title":"JAMA Oncol"},{"issue":"4","key":"2936_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/157340311799960645","volume":"7","author":"M Volkova","year":"2011","unstructured":"Volkova M, Russell R III. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214\u201320.","journal-title":"Curr Cardiol Rev"},{"issue":"6","key":"2936_CR11","first-page":"670","volume":"19","author":"RB Weiss","year":"1992","unstructured":"Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol. 1992;19(6):670\u201386.","journal-title":"Semin Oncol"},{"issue":"2","key":"2936_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","volume":"7","author":"H Cort\u00e9s-Funes","year":"2007","unstructured":"Cort\u00e9s-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol. 2007;7(2):56\u201360.","journal-title":"Cardiovasc Toxicol"},{"issue":"6","key":"2936_CR13","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","volume":"52","author":"Y Octavia","year":"2012","unstructured":"Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213\u201325.","journal-title":"J Mol Cell Cardiol"},{"issue":"13","key":"2936_CR14","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJM199809243391307","volume":"339","author":"PK Singal","year":"1998","unstructured":"Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900\u20135.","journal-title":"N Engl J Med"},{"issue":"2","key":"2936_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000265166","volume":"115","author":"K Chatterjee","year":"2010","unstructured":"Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010;115(2):155\u201362.","journal-title":"Cardiology"},{"key":"2936_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.lfs.2018.05.021","volume":"205","author":"A Jain","year":"2018","unstructured":"Jain A, Rani V. Assessment of herb-drug synergy to combat doxorubicin induced cardiotoxicity. Life Sci. 2018;205:97\u2013106.","journal-title":"Life Sci"},{"issue":"11","key":"2936_CR17","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869\u201379.","journal-title":"Cancer"},{"issue":"3","key":"2936_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10741-020-10028-y","volume":"26","author":"F Jafari","year":"2021","unstructured":"Jafari F, Safaei AM, Hosseini L, Asadian S, Kamangar TM, Zadehbagheri F, Rezaeian N. The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review. Heart Fail Rev. 2021;26(3):679\u201397.","journal-title":"Heart Fail Rev"},{"issue":"24","key":"2936_CR19","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2936_CR20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","volume":"32","author":"EA Lefrak","year":"1973","unstructured":"Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2):302\u201314.","journal-title":"Cancer"},{"key":"2936_CR21","first-page":"7277562","volume":"2022","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Wu L. In vitro and in vivo cardioprotective effects of curcumin against doxorubicin-induced cardiotoxicity: a systematic review. J Oncol. 2022;2022:7277562.","journal-title":"J Oncol"},{"issue":"1","key":"2936_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","volume":"31","author":"JV McGowan","year":"2017","unstructured":"McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63\u201375.","journal-title":"Cardiovasc Drugs Ther"},{"key":"2936_CR23","doi-asserted-by":"publisher","first-page":"117173","DOI":"10.1016\/j.lfs.2019.117173","volume":"241","author":"M Najafi","year":"2020","unstructured":"Najafi M, Hooshangi Shayesteh MR, Mortezaee K, Farhood B, Haghi-Aminjan H. The role of melatonin on doxorubicin-induced cardiotoxicity: a systematic review. Life Sci. 2020;241:117173.","journal-title":"Life Sci"},{"issue":"3","key":"2936_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/biof.1823","volume":"48","author":"H Moutabian","year":"2022","unstructured":"Moutabian H, Ghahramani-Asl R, Mortezazadeh T, Laripour R, Narmani A, Zamani H, Ataei G, Bagheri H, Farhood B, Sathyapalan T, et al. The cardioprotective effects of nano-curcumin against doxorubicin-induced cardiotoxicity: a systematic review. BioFactors. 2022;48(3):597\u2013610.","journal-title":"BioFactors"},{"issue":"4\u20135","key":"2936_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.oraloncology.2008.05.014","volume":"45","author":"PM Specenier","year":"2009","unstructured":"Specenier PM, Vermorken JB. Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol. 2009;45(4\u20135):409\u201315.","journal-title":"Oral Oncol"},{"issue":"6","key":"2936_CR26","doi-asserted-by":"publisher","first-page":"e38557","DOI":"10.1371\/journal.pone.0038557","volume":"7","author":"MB Hannouf","year":"2012","unstructured":"Hannouf MB, Sehgal C, Cao JQ, Mocanu JD, Winquist E, Zaric GS. Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer. PLoS ONE. 2012;7(6):e38557.","journal-title":"PLoS ONE"},{"issue":"9","key":"2936_CR27","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.tranon.2019.06.002","volume":"12","author":"T Higuchi","year":"2019","unstructured":"Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, et al. The combination of olaratumab with doxorubicin and cisplatinum regresses a chemotherapy-resistant osteosarcoma in a patient-derived orthotopic xenograft mouse model. Transl Oncol. 2019;12(9):1257\u201363.","journal-title":"Transl Oncol"},{"issue":"2","key":"2936_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/cancers9020018","volume":"9","author":"R Ruiz-Gonz\u00e1lez","year":"2017","unstructured":"Ruiz-Gonz\u00e1lez R, Mil\u00e1n P, Bresol\u00ed-Obach R, Stockert JC, Villanueva A, Ca\u00f1ete M, Nonell S. Photodynamic synergistic effect of pheophorbide a and doxorubicin in combined treatment against tumoral cells. Cancers. 2017;9(2):18.","journal-title":"Cancers"},{"issue":"12","key":"2936_CR29","first-page":"1483","volume":"22","author":"RF Ahmed","year":"2019","unstructured":"Ahmed RF, Moussa RA, Eldemerdash RS, Zakaria MM, Abdel-Gaber SA. Ameliorative effects of silymarin on HCl-induced acute lung injury in rats; role of the Nrf-2\/HO-1 pathway. Iran J Basic Med Sci. 2019;22(12):1483\u201392.","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"2936_CR30","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/1534735407302349","volume":"6","author":"MC Comelli","year":"2007","unstructured":"Comelli MC, Mengs U, Schneider C, Prosdocimi M. Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther. 2007;6(2):120\u20139.","journal-title":"Integr Cancer Ther"},{"key":"2936_CR31","first-page":"292797","volume":"2015","author":"DR de Oliveira","year":"2015","unstructured":"de Oliveira DR, Tintino SR, Braga MF, Boligon AA, Athayde ML, Coutinho HD, de Menezes IR, Fachinetto R. In vitro antimicrobial and modulatory activity of the natural products silymarin and silibinin. Biomed Res Int. 2015;2015:292797.","journal-title":"Biomed Res Int"},{"issue":"1","key":"2936_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/cld.522","volume":"7","author":"P Ferenci","year":"2016","unstructured":"Ferenci P. Silymarin in the treatment of liver diseases: What is the clinical evidence? Clin Liver Dis. 2016;7(1):8\u201310.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"2936_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0168-8278(89)90083-4","volume":"9","author":"P Ferenci","year":"1989","unstructured":"Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989;9(1):105\u201313.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"2936_CR34","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1002\/ptr.811","volume":"16","author":"J Psotov\u00e1","year":"2002","unstructured":"Psotov\u00e1 J, Chlopc\u00edkov\u00e1 S, Grambal F, Sim\u00e1nek V, Ulrichov\u00e1 J. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res. 2002;16(Suppl 1):S63-67.","journal-title":"Phytother Res"},{"key":"2936_CR35","doi-asserted-by":"crossref","unstructured":"Abenavoli L, Milic N. Chapter 45-silymarin for liver disease. In: Muriel P, editor, Liver pathophysiology. Boston: Academic Press; 2017. p. 621\u201331.","DOI":"10.1016\/B978-0-12-804274-8.00045-X"},{"issue":"3","key":"2936_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/092986707779941159","volume":"14","author":"R Gaz\u00e1k","year":"2007","unstructured":"Gaz\u00e1k R, Walterov\u00e1 D, Kren V. Silybin and silymarin\u2014new and emerging applications in medicine. Curr Med Chem. 2007;14(3):315\u201338.","journal-title":"Curr Med Chem"},{"issue":"2","key":"2936_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1534735407301632","volume":"6","author":"J Post-White","year":"2007","unstructured":"Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther. 2007;6(2):104\u20139.","journal-title":"Integr Cancer Ther"},{"issue":"11","key":"2936_CR38","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1002\/ptr.6470","volume":"33","author":"T Hosseinabadi","year":"2019","unstructured":"Hosseinabadi T, Lorigooini Z, Tabarzad M, Salehi B, Rodrigues CF, Martins N, Sharifi-Rad J. Silymarin antiproliferative and apoptotic effects: insights into its clinical impact in various types of cancer. Phytother Res. 2019;33(11):2849\u201361.","journal-title":"Phytother Res"},{"key":"2936_CR39","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.biopha.2018.03.140","volume":"102","author":"A Taleb","year":"2018","unstructured":"Taleb A, Ahmad KA, Ihsan AU, Qu J, Lin N, Hezam K, Koju N, Hui L, Qilong D. Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases. Biomed Pharmacother. 2018;102:689\u201398.","journal-title":"Biomed Pharmacother"},{"issue":"41","key":"2936_CR40","doi-asserted-by":"publisher","first-page":"57997","DOI":"10.1007\/s11356-021-14722-8","volume":"28","author":"MA Abd Eldaim","year":"2021","unstructured":"Abd Eldaim MA, Barakat ER, Alkafafy M, Elaziz SAA. Antioxidant and anti-apoptotic prophylactic effect of silymarin against lead-induced hepatorenal toxicity in rats. Environ Sci Pollut Res Int. 2021;28(41):57997\u20138006.","journal-title":"Environ Sci Pollut Res Int"},{"key":"2936_CR41","doi-asserted-by":"crossref","unstructured":"Ferraz AC, Almeida LT, da Silva Caetano CC, da Silva Menegatto MB, Souza Lima RL, de Senna JPN, de Oliveira Cardoso JM, Perucci LO, Talvani A, Geraldo de Lima W, et al. Hepatoprotective, antioxidant, anti-inflammatory, and antiviral activities of silymarin against mayaro virus infection. Antiviral Res. 2021; 194:105168.","DOI":"10.1016\/j.antiviral.2021.105168"},{"issue":"4","key":"2936_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/em.22363","volume":"61","author":"TMB Barros","year":"2020","unstructured":"Barros TMB, Lima APB, Almeida TC, da Silva GN. Inhibition of urinary bladder cancer cell proliferation by silibinin. Environ Mol Mutagen. 2020;61(4):445\u201355.","journal-title":"Environ Mol Mutagen"},{"issue":"1","key":"2936_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2174\/138920112798868818","volume":"13","author":"J F\u00e9her","year":"2012","unstructured":"F\u00e9her J, Lengyel G. Silymarin in the prevention and treatment of liver diseases and primary liver cancer. Curr Pharm Biotechnol. 2012;13(1):210\u20137.","journal-title":"Curr Pharm Biotechnol"},{"issue":"6","key":"2936_CR44","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3892\/ol.2021.12753","volume":"21","author":"SH Kim","year":"2021","unstructured":"Kim SH, Choo GS, Yoo ES, Woo JS, Lee JH, Han SH, Jung SH, Kim HJ, Jung JY. Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis. Oncol Lett. 2021;21(6):492.","journal-title":"Oncol Lett"},{"key":"2936_CR45","doi-asserted-by":"crossref","unstructured":"Koltai T, Fliegel L. Role of silymarin in cancer treatment: facts, hypotheses, and questions. J Evidence Based Integr Med. 2022; 27:2515690x211068826.","DOI":"10.1177\/2515690X211068826"},{"issue":"4","key":"2936_CR46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1089\/15230860260220166","volume":"4","author":"RP Singh","year":"2002","unstructured":"Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal. 2002;4(4):655\u201363.","journal-title":"Antioxid Redox Signal"},{"key":"2936_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.biopha.2016.04.039","volume":"81","author":"T Wu","year":"2016","unstructured":"Wu T, Liu W, Guo W, Zhu X. Silymarin suppressed lung cancer growth in mice via inhibiting myeloid-derived suppressor cells. Biomed Pharmacother. 2016;81:460\u20137.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"2936_CR48","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ptr.3618","volume":"26","author":"HC Yu","year":"2012","unstructured":"Yu HC, Chen LJ, Cheng KC, Li YX, Yeh CH, Cheng JT. Silymarin inhibits cervical cancer cell through an increase of phosphatase and tensin homolog. Phytother Res. 2012;26(5):709\u201315.","journal-title":"Phytother Res"},{"issue":"9","key":"2936_CR49","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/carcin\/22.9.1399","volume":"22","author":"W Zhu","year":"2001","unstructured":"Zhu W, Zhang JS, Young CY. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis. 2001;22(9):1399\u2013403.","journal-title":"Carcinogenesis"},{"issue":"9","key":"2936_CR50","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3390\/molecules25092009","volume":"25","author":"D Delmas","year":"2020","unstructured":"Delmas D, Xiao J, Vejux A, Aires V. Silymarin and cancer: a dual strategy in both in chemoprevention and chemosensitivity. Molecules (Basel). 2020;25(9):2009.","journal-title":"Molecules (Basel)"},{"issue":"1","key":"2936_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5507\/bp.2005.002","volume":"149","author":"V Kren","year":"2005","unstructured":"Kren V, Walterov\u00e1 D. Silybin and silymarin\u2014new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia. 2005;149(1):29\u201341.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czechoslovakia"},{"issue":"5","key":"2936_CR52","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1053\/j.gastro.2007.02.038","volume":"132","author":"SJ Polyak","year":"2007","unstructured":"Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology. 2007;132(5):1925\u201336.","journal-title":"Gastroenterology"},{"issue":"1","key":"2936_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000113648","volume":"15","author":"R Saller","year":"2008","unstructured":"Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forschende Komplementarmedizin. 2008;15(1):9\u201320.","journal-title":"Forschende Komplementarmedizin"},{"issue":"3","key":"2936_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tox.2006.07.021","volume":"227","author":"X Zhong","year":"2006","unstructured":"Zhong X, Zhu Y, Lu Q, Zhang J, Ge Z, Zheng S. Silymarin causes caspases activation and apoptosis in K562 leukemia cells through inactivation of Akt pathway. Toxicology. 2006;227(3):211\u20136.","journal-title":"Toxicology"},{"issue":"4","key":"2936_CR55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2936_CR56","doi-asserted-by":"publisher","first-page":"767","DOI":"10.21873\/anticanres.15535","volume":"42","author":"E Ortona","year":"2022","unstructured":"Ortona E, Locatelli SL, Pagano MT, Ascione B, Careddu G, Dupuis ML, Marconi M, Carlo-Stella C, Malorni W, Matarrese P, et al. The natural estrogen receptor beta agonist silibinin as a promising therapeutic tool in diffuse large B-cell lymphoma. Anticancer Res. 2022;42(2):767\u201379.","journal-title":"Anticancer Res"},{"issue":"2","key":"2936_CR57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.taap.2010.02.002","volume":"245","author":"N Patel","year":"2010","unstructured":"Patel N, Joseph C, Corcoran GB, Ray SD. Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol Appl Pharmacol. 2010;245(2):143\u201352.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"11","key":"2936_CR58","first-page":"574","volume":"65","author":"W Arozal","year":"2015","unstructured":"Arozal W, Suyatna FD, Juniantito V, Rosdiana DS, Amurugam S, Aulia R, Monayo ER, Siswandi R. The effects of mangiferin (Mangifera indica L.) in doxorubicin-induced cardiotoxicity in rats. Drug Res. 2015;65(11):574\u201380.","journal-title":"Drug Res"},{"issue":"10","key":"2936_CR59","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.3390\/molecules16108601","volume":"16","author":"A Ra\u0161kovi\u0107","year":"2011","unstructured":"Ra\u0161kovi\u0107 A, Stilinovi\u0107 N, Kolarovi\u0107 J, Vasovi\u0107 V, Vukmirovi\u0107 S, Mikov M. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules (Basel). 2011;16(10):8601\u201313.","journal-title":"Molecules (Basel)"},{"key":"2936_CR60","doi-asserted-by":"crossref","unstructured":"Afsar T, Razak S, Batoo KM, Khan MR. Acacia hydaspica R. Parker prevents doxorubicin-induced cardiac injury by attenuation of oxidative stress and structural Cardiomyocyte alterations in rats. BMC Complement Altern Med. 2017; 17(1):554.","DOI":"10.1186\/s12906-017-2061-0"},{"issue":"2","key":"2936_CR61","first-page":"133","volume":"19","author":"AA Hagag","year":"2019","unstructured":"Hagag AA, El Shehaby WA, El-Abasy AI, Mabrouk MM. Protective role of silymarin in early doxorubicin-induced cardiac dysfunction in children with acute lymphoblastic leukemia. Infect Disord Drug Targets. 2019;19(2):133\u201340.","journal-title":"Infect Disord Drug Targets"},{"issue":"7","key":"2936_CR62","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.fct.2008.03.033","volume":"46","author":"NA El-Shitany","year":"2008","unstructured":"El-Shitany NA, El-Haggar S, El-desoky K. Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol. 2008;46(7):2422\u20138.","journal-title":"Food Chem Toxicol"},{"issue":"10","key":"2936_CR63","first-page":"2697","volume":"12","author":"E Cecen","year":"2011","unstructured":"Cecen E, Dost T, Culhaci N, Karul A, Ergur B, Birincioglu M. Protective effects of silymarin against doxorubicin-induced toxicity. Asian Pac J Cancer Prev. 2011;12(10):2697\u2013704.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"2936_CR64","first-page":"4158","volume":"10","author":"GM Attia","year":"2017","unstructured":"Attia GM, Elmansy RA, Algaidi SA. Silymarin decreases the expression of VEGF-A, iNOS and caspase-3 and preserves the ultrastructure of cardiac cells in doxorubicin induced cardiotoxicity in rats: a possible protective role. Int J Clin Exp Med. 2017;10(2):4158\u201373.","journal-title":"Int J Clin Exp Med"},{"key":"2936_CR65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.biopha.2018.11.053","volume":"110","author":"HM Abdelsalam","year":"2019","unstructured":"Abdelsalam HM, Samak MA, Alsemeh AE. Synergistic therapeutic effects of Vitis vinifera extract and Silymarin on experimentally induced cardiorenal injury: the pertinent role of Nrf2. Biomed Pharmacother. 2019;110:37\u201346.","journal-title":"Biomed Pharmacother"},{"key":"2936_CR66","doi-asserted-by":"publisher","first-page":"e01244","DOI":"10.1016\/j.sciaf.2022.e01244","volume":"16","author":"OA Akinloye","year":"2022","unstructured":"Akinloye OA, Sulaimon LA, Adewale AO, Mubaraq T, Salami O, Abiola O. Allium vineale methanol extract attenuated oxidative stress and inflammation induced by doxorubicin in Sprague Dawley Rats. Scientific African. 2022;16:e01244.","journal-title":"Scientific African"},{"key":"2936_CR67","doi-asserted-by":"crossref","unstructured":"Chlopc\u00edkov\u00e1 S, Psotov\u00e1 J, Miketov\u00e1 P, Sim\u00e1nek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res. 2004; 18(2):107\u201310.","DOI":"10.1002\/ptr.1415"},{"issue":"5\u20136","key":"2936_CR68","first-page":"353","volume":"23","author":"L Chrostek","year":"1989","unstructured":"Chrostek L, Szmitkowski M. Enzymatic diagnosis of alcoholism-induced damage of internal organs. Psychiatr Pol. 1989;23(5\u20136):353\u201360.","journal-title":"Psychiatr Pol"},{"issue":"12","key":"2936_CR69","first-page":"2514","volume":"5","author":"RK Muhammad","year":"2011","unstructured":"Muhammad RK, Javeria H, Rahmat AK, Jasia B, Maria S, Umbreen R. Prevention of KBr O3-induced cardiotoxicity by Sonchus asper in rat. J Med Plants Res. 2011;5(12):2514\u201320.","journal-title":"J Med Plants Res"},{"issue":"23","key":"2936_CR70","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474\u201381.","journal-title":"Circulation"},{"issue":"8","key":"2936_CR71","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1177\/0192623313482056","volume":"41","author":"WJ Reagan","year":"2013","unstructured":"Reagan WJ, York M, Berridge B, Schultze E, Walker D, Pettit S. Comparison of cardiac troponin I and T, including the evaluation of an ultrasensitive assay, as indicators of doxorubicin-induced cardiotoxicity. Toxicol Pathol. 2013;41(8):1146\u201358.","journal-title":"Toxicol Pathol"},{"key":"2936_CR72","doi-asserted-by":"crossref","unstructured":"al-Harbi MM, al-Gharably NM, al-Shabanah OA, al-Bekairi AM, Osman AM, Tawfik HN. Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemother Pharmacol. 1992; 31(3):200\u20134.","DOI":"10.1007\/BF00685548"},{"issue":"7","key":"2936_CR73","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1538-7836.2009.03477.x","volume":"7","author":"EJ Kim","year":"2009","unstructured":"Kim EJ, Lim KM, Kim KY, Bae ON, Noh JY, Chung SM, Shin S, Yun YP, Chung JH. Doxorubicin-induced platelet cytotoxicity: a new contributory factor for doxorubicin-mediated thrombocytopenia. J Thromb Haemost. 2009;7(7):1172\u201383.","journal-title":"J Thromb Haemost"},{"key":"2936_CR74","doi-asserted-by":"publisher","first-page":"102089","DOI":"10.1016\/j.redox.2021.102089","volume":"46","author":"D Li","year":"2021","unstructured":"Li D, Yang Y, Wang S, He X, Liu M, Bai B, Tian C, Sun R, Yu T, Chu X. Role of acetylation in doxorubicin-induced cardiotoxicity. Redox Biol. 2021;46:102089.","journal-title":"Redox Biol"},{"issue":"5","key":"2936_CR75","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.fct.2011.01.021","volume":"49","author":"L Hosseinzadeh","year":"2011","unstructured":"Hosseinzadeh L, Behravan J, Mosaffa F, Bahrami G, Bahrami A, Karimi G. Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem Toxicol. 2011;49(5):1102\u20139.","journal-title":"Food Chem Toxicol"},{"issue":"8","key":"2936_CR76","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1039\/C8FO00466H","volume":"9","author":"H He","year":"2018","unstructured":"He H, Luo Y, Qiao Y, Zhang Z, Yin D, Yao J, You J, He M. Curcumin attenuates doxorubicin-induced cardiotoxicity via suppressing oxidative stress and preventing mitochondrial dysfunction mediated by 14-3-3\u03b3. Food Funct. 2018;9(8):4404\u201318.","journal-title":"Food Funct"},{"issue":"1\u20132","key":"2936_CR77","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11010-017-3195-6","volume":"442","author":"A Jain","year":"2018","unstructured":"Jain A, Rani V. Mode of treatment governs curcumin response on doxorubicin-induced toxicity in cardiomyoblasts. Mol Cell Biochem. 2018;442(1\u20132):81\u201396.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"2936_CR78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/1534735414564425","volume":"14","author":"MT Sheu","year":"2015","unstructured":"Sheu MT, Jhan HJ, Hsieh CM, Wang CJ, Ho HO. Efficacy of antioxidants as a Complementary and Alternative Medicine (CAM) in combination with the chemotherapeutic agent doxorubicin. Integr Cancer Ther. 2015;14(2):184\u201395.","journal-title":"Integr Cancer Ther"},{"issue":"9","key":"2936_CR79","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/nu10091304","volume":"10","author":"V Quagliariello","year":"2018","unstructured":"Quagliariello V, Vecchione R, Coppola C, Di Cicco C, De Capua A, Piscopo G, Paciello R, Narciso V, Formisano C, Taglialatela-Scafati O, et al. Cardioprotective effects of nanoemulsions loaded with anti-inflammatory nutraceuticals against doxorubicin-induced cardiotoxicity. Nutrients. 2018;10(9):1304.","journal-title":"Nutrients"},{"issue":"5","key":"2936_CR80","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3892\/etm.2013.989","volume":"5","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Li L, Xiang C, Ma Z, Ma T, Zhu S. Protective effect of melatonin against Adriamycin-induced cardiotoxicity. Exp Ther Med. 2013;5(5):1496\u2013500.","journal-title":"Exp Ther Med"},{"issue":"1\u20132","key":"2936_CR81","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijpharm.2012.04.062","volume":"432","author":"Y Sadzuka","year":"2012","unstructured":"Sadzuka Y, Nagamine M, Toyooka T, Ibuki Y, Sonobe T. Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. Int J Pharm. 2012;432(1\u20132):42\u20139.","journal-title":"Int J Pharm"},{"issue":"3","key":"2936_CR82","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s13105-014-0339-y","volume":"70","author":"MH Arafa","year":"2014","unstructured":"Arafa MH, Mohammad NS, Atteia HH, Abd-Elaziz HR. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem. 2014;70(3):701\u201311.","journal-title":"J Physiol Biochem"},{"issue":"8","key":"2936_CR83","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s12094-017-1828-6","volume":"20","author":"R Yahyapour","year":"2018","unstructured":"Yahyapour R, Motevaseli E, Rezaeyan A, Abdollahi H, Farhood B, Cheki M, Rezapoor S, Shabeeb D, Musa AE, Najafi M, et al. Reduction-oxidation (redox) system in radiation-induced normal tissue injury: molecular mechanisms and implications in radiation therapeutics. Clin Transl Oncol. 2018;20(8):975\u201388.","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"2936_CR84","first-page":"1805","volume":"77","author":"A Hasan Kadhim","year":"2022","unstructured":"Hasan Kadhim A, Shamkhi Noor A, Amer AM. The effectiveness of biotin (Vitamin B7) added to the diet in improving the efficiency of productivity, and some physiological traits for broiler chickens (Ross-308) Exposed to Oxidative Stress. Arch Razi Inst. 2022;77(5):1805\u201311.","journal-title":"Arch Razi Inst"},{"issue":"2","key":"2936_CR85","first-page":"853","volume":"77","author":"S Varadhan","year":"2022","unstructured":"Varadhan S, Venkatachalam R, Perumal S, Ayyamkulamkara S. Evaluation of oxidative stress parameters and antioxidant status in coronary artery disease patients. Arch Razi Inst. 2022;77(2):853\u20139.","journal-title":"Arch Razi Inst"},{"issue":"2","key":"2936_CR86","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3892\/etm.2016.3437","volume":"12","author":"MH Liu","year":"2016","unstructured":"Liu MH, Shan J, Li J, Zhang Y, Lin XL. Resveratrol inhibits doxorubicin-induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes. Exp Ther Med. 2016;12(2):1113\u20138.","journal-title":"Exp Ther Med"},{"issue":"3","key":"2936_CR87","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/10715760802673008","volume":"43","author":"E Tatlidede","year":"2009","unstructured":"Tatlidede E, Sehirli O, Velio\u011flu-O\u011f\u00fcnc A, Cetinel S, Ye\u011fen BC, Yarat A, S\u00fcleymano\u011flu S, Sener G. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radical Res. 2009;43(3):195\u2013205.","journal-title":"Free Radical Res"},{"issue":"2","key":"2936_CR88","doi-asserted-by":"publisher","first-page":"E243","DOI":"10.1152\/ajpendo.00044.2013","volume":"305","author":"VW Dolinsky","year":"2013","unstructured":"Dolinsky VW, Rogan KJ, Sung MM, Zordoky BN, Haykowsky MJ, Young ME, Jones LW, Dyck JR. Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol Metab. 2013;305(2):E243-253.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"2936_CR89","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/antiox9020159","volume":"9","author":"AM Alanazi","year":"2020","unstructured":"Alanazi AM, Fadda L, Alhusaini A, Ahmad R, Hasan IH, Mahmoud AM. Liposomal resveratrol and\/or carvedilol attenuate doxorubicin-induced cardiotoxicity by modulating inflammation, oxidative stress and S100A1 in rats. Antioxidants (Basel). 2020;9(2):159.","journal-title":"Antioxidants (Basel)"},{"key":"2936_CR90","doi-asserted-by":"publisher","first-page":"606183","DOI":"10.1155\/2012\/606183","volume":"2012","author":"J Dudka","year":"2012","unstructured":"Dudka J, Gieroba R, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, Mandziuk S, Korobowicz E, Murias M. Different effects of resveratrol on dose-related Doxorubicin-induced heart and liver toxicity. Evidence Based Complement Altern Med. 2012;2012:606183.","journal-title":"Evidence Based Complement Altern Med"},{"issue":"3","key":"2936_CR91","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.3892\/mmr.2014.2384","volume":"10","author":"SE Al-Harthi","year":"2014","unstructured":"Al-Harthi SE, Alarabi OM, Ramadan WS, Alaama MN, Al-Kreathy HM, Damanhouri ZA, Khan LM, Osman AM. Amelioration of doxorubicin-induced cardiotoxicity by resveratrol. Mol Med Rep. 2014;10(3):1455\u201360.","journal-title":"Mol Med Rep"},{"issue":"5","key":"2936_CR92","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.phymed.2015.03.014","volume":"22","author":"HL Wang","year":"2015","unstructured":"Wang HL, Gao JP, Han YL, Xu X, Wu R, Gao Y, Cui XH. Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo. Phytomedicine. 2015;22(5):553\u20139.","journal-title":"Phytomedicine"},{"issue":"4","key":"2936_CR93","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.foodres.2011.03.034","volume":"44","author":"K Mukherjee","year":"2011","unstructured":"Mukherjee K, Venkatesh M, Venkatesh P, Saha BP, Mukherjee PK. Effect of soy phosphatidyl choline on the bioavailability and nutritional health benefits of resveratrol. Food Res Int. 2011;44(4):1088\u201393.","journal-title":"Food Res Int"},{"issue":"6","key":"2936_CR94","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacbts.2018.06.005","volume":"3","author":"AZ Luu","year":"2018","unstructured":"Luu AZ, Chowdhury B, Al-Omran M, Teoh H, Hess DA, Verma S. Role of endothelium in doxorubicin-induced cardiomyopathy. JACC Basic Transl Sci. 2018;3(6):861\u201370.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"2936_CR95","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jacc.2017.05.035","volume":"70","author":"T M\u00fcnzel","year":"2017","unstructured":"M\u00fcnzel T, Camici GG, Maack C, Bonetti NR, Fuster V, Kovacic JC. Impact of oxidative stress on the heart and vasculature: part 2 of a 3-part series. J Am Coll Cardiol. 2017;70(2):212\u201329.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2936_CR96","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0960327111426589","volume":"31","author":"MA Rezvanfar","year":"2012","unstructured":"Rezvanfar MA, Rezvanfar MA, Ahmadi A, Saadi HA, Baeeri M, Abdollahi M. Mechanistic links between oxidative\/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary: biochemical and pathological evidences for beneficial effect of pioglitazone. Hum Exp Toxicol. 2012;31(9):887\u201397.","journal-title":"Hum Exp Toxicol"},{"issue":"12","key":"2936_CR97","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.freeradbiomed.2009.03.011","volume":"46","author":"ED Danz","year":"2009","unstructured":"Danz ED, Skramsted J, Henry N, Bennett JA, Keller RS. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radical Biol Med. 2009;46(12):1589\u201397.","journal-title":"Free Radical Biol Med"},{"issue":"4","key":"2936_CR98","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.bbadis.2018.08.025","volume":"1865","author":"J Dudek","year":"2019","unstructured":"Dudek J, Hartmann M, Rehling P. The role of mitochondrial cardiolipin in heart function and its implication in cardiac disease. Biochim Biophys Acta. 2019;1865(4):810\u201321.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2936_CR99","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, Mutharasan RK, Naik TJ, Ardehali H. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Investig. 2014;124(2):617\u201330.","journal-title":"J Clin Investig"},{"issue":"4","key":"2936_CR100","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/molecules27041320","volume":"27","author":"RA Syahputra","year":"2022","unstructured":"Syahputra RA, Harahap U, Dalimunthe A, Nasution MP, Satria D. The role of flavonoids as a cardioprotective strategy against doxorubicin-induced cardiotoxicity: a review. Molecules. 2022;27(4):1320.","journal-title":"Molecules"},{"issue":"1","key":"2936_CR101","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/antiox4010204","volume":"4","author":"PF Surai","year":"2015","unstructured":"Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants. 2015;4(1):204\u201347.","journal-title":"Antioxidants"},{"issue":"17","key":"2936_CR102","doi-asserted-by":"publisher","first-page":"17226","DOI":"10.1007\/s11356-016-6934-4","volume":"23","author":"SA Sheweita","year":"2016","unstructured":"Sheweita SA, Al-Shora S, Hassan M. Effects of benzo [a]pyrene as an environmental pollutant and two natural antioxidants on biomarkers of reproductive dysfunction in male rats. Environ Sci Pollut Res Int. 2016;23(17):17226\u201335.","journal-title":"Environ Sci Pollut Res Int"},{"issue":"16","key":"2936_CR103","first-page":"863","volume":"131","author":"G M\u00fczes","year":"1990","unstructured":"M\u00fczes G, De\u00e1k G, L\u00e1ng I, N\u00e9k\u00e1m K, Niederland V, Feh\u00e9r J. Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol). Orv Hetil. 1990;131(16):863\u20136.","journal-title":"Orv Hetil"},{"issue":"3","key":"2936_CR104","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jep.2007.10.024","volume":"115","author":"H Ligeret","year":"2008","unstructured":"Ligeret H, Brault A, Vallerand D, Haddad Y, Haddad PS. Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. J Ethnopharmacol. 2008;115(3):507\u201314.","journal-title":"J Ethnopharmacol"},{"key":"2936_CR105","doi-asserted-by":"publisher","first-page":"145239","DOI":"10.1016\/j.gene.2020.145239","volume":"769","author":"A Yard\u0131m","year":"2021","unstructured":"Yard\u0131m A, Kucukler S, \u00d6zdemir S, \u00c7omakl\u0131 S, Caglayan C, Kandemir FM, \u00c7elik H. Silymarin alleviates docetaxel-induced central and peripheral neurotoxicity by reducing oxidative stress, inflammation and apoptosis in rats. Gene. 2021;769:145239.","journal-title":"Gene"},{"key":"2936_CR106","doi-asserted-by":"crossref","unstructured":"Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochimica et Biophysica Acta. 2016; 1863(7 Pt B):1916\u201325.","DOI":"10.1016\/j.bbamcr.2016.01.021"},{"issue":"4","key":"2936_CR107","first-page":"762","volume":"15","author":"B Liu","year":"2007","unstructured":"Liu B, Bai QX, Chen XQ, Gao GX, Gu HT. Effect of curcumin on expression of survivin, Bcl-2 and Bax in human multiple myeloma cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15(4):762\u20136.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2936_CR108","doi-asserted-by":"crossref","unstructured":"Shi Y, Moon M, Dawood S, McManus B, Liu PP. Mechanisms and management of doxorubicin cardiotoxicity. Herz. 2011; 36(4):296\u2013305.","DOI":"10.1007\/s00059-011-3470-3"},{"issue":"2","key":"2936_CR109","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/mol.119.115725","volume":"96","author":"N Wenningmann","year":"2019","unstructured":"Wenningmann N, Knapp M, Ande A, Vaidya TR, Ait-Oudhia S. Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring. Mol Pharmacol. 2019;96(2):219\u201332.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"2936_CR110","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/157339611796892265","volume":"7","author":"J Shi","year":"2011","unstructured":"Shi J, Abdelwahid E, Wei L. Apoptosis in anthracycline cardiomyopathy. Curr Pediatr Rev. 2011;7(4):329\u201336.","journal-title":"Curr Pediatr Rev"},{"issue":"6","key":"2936_CR111","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1096\/fj.03-0724rev","volume":"18","author":"S Fogli","year":"2004","unstructured":"Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004;18(6):664\u201375.","journal-title":"FASEB J"},{"issue":"3","key":"2936_CR112","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/BF02899922","volume":"3","author":"O Csuka","year":"1997","unstructured":"Csuka O, Remen\u00e1r E, Koronczay K, Doleschall Z, N\u00e9meth G. Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer. Pathol Oncol Res. 1997;3(3):204\u201310.","journal-title":"Pathol Oncol Res"},{"issue":"3","key":"2936_CR113","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/oxfordjournals.bmb.a011629","volume":"53","author":"A Haimovitz-Friedman","year":"1997","unstructured":"Haimovitz-Friedman A, Kolesnick RN, Fuks Z. Ceramide signaling in apoptosis. Br Med Bull. 1997;53(3):539\u201353.","journal-title":"Br Med Bull"},{"issue":"2","key":"2936_CR114","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.surg.2013.03.012","volume":"154","author":"S Huerta","year":"2013","unstructured":"Huerta S, Gao X, Dineen S, Kapur P, Saha D, Meyer J. Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts. Surgery. 2013;154(2):143\u201351.","journal-title":"Surgery"},{"issue":"22","key":"2936_CR115","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.3390\/ijms20225691","volume":"20","author":"H Kim","year":"2019","unstructured":"Kim H, Yoo WS, Jung JH, Jeong BK, Woo SH, Kim JH, Kim SJ. Alpha-lipoic acid ameliorates radiation-induced lacrimal gland injury through NFAT5-dependent signaling. Int J Mol Sci. 2019;20(22):5691.","journal-title":"Int J Mol Sci"},{"key":"2936_CR116","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.lfs.2019.05.009","volume":"228","author":"K Mortezaee","year":"2019","unstructured":"Mortezaee K, Najafi M, Farhood B, Ahmadi A, Potes Y, Shabeeb D, Musa AE. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: an updated review. Life Sci. 2019;228:228\u201341.","journal-title":"Life Sci"},{"issue":"1","key":"2936_CR117","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12935-022-02561-7","volume":"22","author":"H Moutabian","year":"2022","unstructured":"Moutabian H, Majdaeen M, Ghahramani-Asl R, Yadollahi M, Gharepapagh E, Ataei G, Falahatpour Z, Bagheri H, Farhood B. A systematic review of the therapeutic effects of resveratrol in combination with 5-fluorouracil during colorectal cancer treatment: with a special focus on the oxidant, apoptotic, and anti-inflammatory activities. Cancer Cell Int. 2022;22(1):142.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"2936_CR118","doi-asserted-by":"publisher","first-page":"e0181535","DOI":"10.1371\/journal.pone.0181535","volume":"12","author":"HS Shoukry","year":"2017","unstructured":"Shoukry HS, Ammar HI, Rashed LA, Zikri MB, Shamaa AA, Abou Elfadl SG, Rub EA, Saravanan S, Dhingra S. Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity. PLoS ONE. 2017;12(7):e0181535.","journal-title":"PLoS ONE"},{"issue":"9","key":"2936_CR119","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1039\/C9FO01034C","volume":"10","author":"R Wu","year":"2019","unstructured":"Wu R, Mei X, Wang J, Sun W, Xue T, Lin C, Xu D. Zn(ii)-Curcumin supplementation alleviates gut dysbiosis and zinc dyshomeostasis during doxorubicin-induced cardiotoxicity in rats. Food Funct. 2019;10(9):5587\u2013604.","journal-title":"Food Funct"},{"issue":"4","key":"2936_CR120","doi-asserted-by":"publisher","first-page":"752","DOI":"10.21037\/cdt-19-707","volume":"10","author":"W Yu","year":"2020","unstructured":"Yu W, Qin X, Zhang Y, Qiu P, Wang L, Zha W, Ren J. Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K\/Akt\/mTOR-dependent manner. Cardiovasc Diagn Therapy. 2020;10(4):752\u201369.","journal-title":"Cardiovasc Diagn Therapy"},{"issue":"1","key":"2936_CR121","first-page":"49","volume":"14","author":"L Hosseinzadeh","year":"2011","unstructured":"Hosseinzadeh L, Behravan J, Mosaffa F, Bahrami G, Bahrami AR, Karimi G. Effect of curcumin on doxorubicin-induced cytotoxicity in H9c2 cardiomyoblast cells. Iran J Basic Med Sci. 2011;14(1):49\u201356.","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"2936_CR122","doi-asserted-by":"publisher","first-page":"e22030","DOI":"10.1002\/jbt.22030","volume":"32","author":"F Benzer","year":"2018","unstructured":"Benzer F, Kandemir FM, Ozkaraca M, Kucukler S, Caglayan C. Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats. J Biochem Mol Toxicol. 2018;32(2):e22030.","journal-title":"J Biochem Mol Toxicol"},{"issue":"2","key":"2936_CR123","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3892\/mmr.2015.4665","volume":"13","author":"MH Liu","year":"2016","unstructured":"Liu MH, Lin XL, Guo DM, Zhang Y, Yuan C, Tan TP, Chen YD, Wu SJ, Ye ZF, He J. Resveratrol protects cardiomyocytes from doxorubicin-induced apoptosis through the AMPK\/P53 pathway. Mol Med Rep. 2016;13(2):1281\u20136.","journal-title":"Mol Med Rep"},{"issue":"3","key":"2936_CR124","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/cvr\/cvr022","volume":"90","author":"C Zhang","year":"2011","unstructured":"Zhang C, Feng Y, Qu S, Wei X, Zhu H, Luo Q, Liu M, Chen G, Xiao X. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res. 2011;90(3):538\u201345.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"2936_CR125","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.bcp.2011.01.008","volume":"81","author":"J Das","year":"2011","unstructured":"Das J, Ghosh J, Manna P, Sil PC. Taurine suppresses doxorubicin-triggered oxidative stress and cardiac apoptosis in rat via up-regulation of PI3-K\/Akt and inhibition of p53, p38-JNK. Biochem Pharmacol. 2011;81(7):891\u2013909.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"2936_CR126","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1684\/ecn.2013.0341","volume":"24","author":"IO Sherif","year":"2013","unstructured":"Sherif IO, Al-Gayyar MM. Antioxidant, anti-inflammatory and hepatoprotective effects of silymarin on hepatic dysfunction induced by sodium nitrite. Eur Cytokine Netw. 2013;24(3):114\u201321.","journal-title":"Eur Cytokine Netw"},{"issue":"4","key":"2936_CR127","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1742-7843.2007.00116.x","volume":"101","author":"Z Song","year":"2007","unstructured":"Song Z, Song M, Lee DY, Liu Y, Deaciuc IV, McClain CJ. Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. Basic Clin Pharmacol Toxicol. 2007;101(4):262\u20138.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"2936_CR128","doi-asserted-by":"publisher","first-page":"e12398","DOI":"10.1111\/jfbc.12398","volume":"41","author":"FM Kandemir","year":"2017","unstructured":"Kandemir FM, Kucukler S, Caglayan C, Gur C, Batil AA, G\u00fcl\u00e7in \u0130. Therapeutic effects of silymarin and naringin on methotrexate-induced nephrotoxicity in rats: Biochemical evaluation of anti-inflammatory, antiapoptotic, and antiautophagic properties. J Food Biochem. 2017;41(5):e12398.","journal-title":"J Food Biochem"},{"issue":"6","key":"2936_CR129","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.etp.2010.04.009","volume":"63","author":"S Aghazadeh","year":"2011","unstructured":"Aghazadeh S, Amini R, Yazdanparast R, Ghaffari SH. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis. Exp Toxicol Pathol. 2011;63(6):569\u201374.","journal-title":"Exp Toxicol Pathol"},{"issue":"2","key":"2936_CR130","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1158\/1535-7163.207.4.2","volume":"4","author":"SK Katiyar","year":"2005","unstructured":"Katiyar SK, Roy AM, Baliga MS. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2\/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther. 2005;4(2):207\u201316.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2936_CR131","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.4049\/jimmunol.163.12.6800","volume":"163","author":"SK Manna","year":"1999","unstructured":"Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol. 1999;163(12):6800\u20139.","journal-title":"J Immunol"},{"key":"2936_CR132","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2147\/OTT.S60114","volume":"7","author":"D Vyas","year":"2014","unstructured":"Vyas D, Laput G, Vyas AK. Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. Onco Targets Ther. 2014;7:1015\u201323.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"2936_CR133","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1002\/jcp.27442","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Mortezaee K, Goradel NH, Khanlarkhani N, Salehi E, Nashtaei MS, Najafi M, Sahebkar A. Curcumin as an anti-inflammatory agent: Implications to radiotherapy and chemotherapy. J Cell Physiol. 2019;234(5):5728\u201340.","journal-title":"J Cell Physiol"},{"issue":"8","key":"2936_CR134","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1080\/1061186X.2017.1315687","volume":"25","author":"J Peng","year":"2017","unstructured":"Peng J, Fumoto S, Miyamoto H, Chen Y, Kuroda N, Nishida K. One-step formation of lipid-polyacrylic acid-calcium carbonate nanoparticles for co-delivery of doxorubicin and curcumin. J Drug Target. 2017;25(8):704\u201314.","journal-title":"J Drug Target"},{"issue":"12","key":"2936_CR135","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1021\/acs.molpharmaceut.0c00718","volume":"17","author":"N Wang","year":"2020","unstructured":"Wang N, Zhang Y, Liu H, Wang A, Ren T, Gou J, Zhang Y, Yin T, He H, Tang X. Toxicity reduction and efficacy promotion of doxorubicin in the treatment of breast tumors assisted by enhanced oral absorption of curcumin-loaded lipid-polyester mixed nanoparticles. Mol Pharm. 2020;17(12):4533\u201347.","journal-title":"Mol Pharm"},{"issue":"6","key":"2936_CR136","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jhep.2009.02.023","volume":"50","author":"M Trappoliere","year":"2009","unstructured":"Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50(6):1102\u201311.","journal-title":"J Hepatol"},{"issue":"5","key":"2936_CR137","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.phrs.2009.12.017","volume":"61","author":"M Gharagozloo","year":"2010","unstructured":"Gharagozloo M, Velardi E, Bruscoli S, Agostini M, Di Sante M, Donato V, Amirghofran Z, Riccardi C. Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production. Pharmacol Res. 2010;61(5):405\u20139.","journal-title":"Pharmacol Res"},{"issue":"5","key":"2936_CR138","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.fct.2012.02.025","volume":"50","author":"CC Li","year":"2012","unstructured":"Li CC, Hsiang CY, Wu SL, Ho TY. Identification of novel mechanisms of silymarin on the carbon tetrachloride-induced liver fibrosis in mice by nuclear factor-\u03baB bioluminescent imaging-guided transcriptomic analysis. Food Chem Toxicol. 2012;50(5):1568\u201375.","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"2936_CR139","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3892\/etm.2016.3370","volume":"12","author":"Y Jin","year":"2016","unstructured":"Jin Y, Zhao X, Zhang H, Li Q, Lu G, Zhao X. Modulatory effect of silymarin on pulmonary vascular dysfunction through HIF-1\u03b1-iNOS following rat lung ischemia-reperfusion injury. Exp Ther Med. 2016;12(2):1135\u201340.","journal-title":"Exp Ther Med"},{"issue":"2","key":"2936_CR140","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jss.2016.04.069","volume":"204","author":"NN Younis","year":"2016","unstructured":"Younis NN, Shaheen MA, Mahmoud MF. Silymarin preconditioning protected insulin resistant rats from liver ischemia-reperfusion injury: role of endogenous H2S. J Surg Res. 2016;204(2):398\u2013409.","journal-title":"J Surg Res"},{"key":"2936_CR141","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cbi.2017.06.022","volume":"273","author":"W Arafa Keshk","year":"2017","unstructured":"Arafa Keshk W, Zahran SM, Katary MA, Abd-Elaziz AD. Modulatory effect of silymarin on nuclear factor-erythroid-2-related factor 2 regulated redox status, nuclear factor-\u03baB mediated inflammation and apoptosis in experimental gastric ulcer. Chem Biol Interact. 2017;273:266\u201372.","journal-title":"Chem Biol Interact"},{"issue":"9","key":"2936_CR142","first-page":"968","volume":"22","author":"V Akbari-Kordkheyli","year":"2019","unstructured":"Akbari-Kordkheyli V, Abbaszadeh-Goudarzi K, Nejati-Laskokalayeh M, Zarpou S, Khonakdar-Tarsi A. The protective effects of silymarin on ischemia-reperfusion injuries: a mechanistic review. Iran J Basic Med Sci. 2019;22(9):968\u201376.","journal-title":"Iran J Basic Med Sci"},{"issue":"2","key":"2936_CR143","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.canlet.2008.03.053","volume":"269","author":"K Ramasamy","year":"2008","unstructured":"Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett. 2008;269(2):352\u201362.","journal-title":"Cancer Lett"},{"issue":"1","key":"2936_CR144","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/vms3.641","volume":"8","author":"R Khazaei","year":"2022","unstructured":"Khazaei R, Seidavi A, Bouyeh M. A review on the mechanisms of the effect of silymarin in milk thistle (Silybum marianum) on some laboratory animals. Vet Med Sci. 2022;8(1):289\u2013301.","journal-title":"Vet Med Sci"},{"issue":"6","key":"2936_CR145","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/ptr.6361","volume":"33","author":"V Soleimani","year":"2019","unstructured":"Soleimani V, Delghandi PS, Moallem SA, Karimi G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review. Phytother Res. 2019;33(6):1627\u201338.","journal-title":"Phytother Res"},{"key":"2936_CR146","doi-asserted-by":"crossref","unstructured":"Bijak M. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)-chemistry, bioavailability, and metabolism. Molecules. 2017; 22(11):1942.","DOI":"10.3390\/molecules22111942"},{"issue":"4","key":"2936_CR147","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s12325-020-01251-y","volume":"37","author":"A Gillessen","year":"2020","unstructured":"Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020;37(4):1279\u2013301.","journal-title":"Adv Ther"},{"key":"2936_CR148","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fphar.2017.00498","volume":"8","author":"H Amawi","year":"2017","unstructured":"Amawi H, Hussein NA, Karthikeyan C, Manivannan E, Wisner A, Williams FE, Samuel T, Trivedi P, Ashby CR Jr, Tiwari AK. HM015k, a novel silybin derivative, multi-targets metastatic ovarian cancer cells and is safe in zebrafish toxicity Studies. Front Pharmacol. 2017;8:498.","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"2936_CR149","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1002\/ptr.796","volume":"16","author":"P Kosina","year":"2002","unstructured":"Kosina P, Kren V, Gebhardt R, Grambal F, Ulrichov\u00e1 J, Walterov\u00e1 D. Antioxidant properties of silybin glycosides. Phytother Res. 2002;16(Suppl 1):S33-39.","journal-title":"Phytother Res"},{"issue":"5","key":"2936_CR150","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/antiox9050455","volume":"9","author":"S Dobiasov\u00e1","year":"2020","unstructured":"Dobiasov\u00e1 S, \u0158eho\u0159ov\u00e1 K, Ku\u010derov\u00e1 D, Biedermann D, K\u00e1\u0148ov\u00e1 K, Petr\u00e1skov\u00e1 L, Kouck\u00e1 K, V\u00e1clav\u00edkov\u00e1 R, Valentov\u00e1 K, Ruml T, et al. Multidrug resistance modulation activity of silybin derivatives and their anti-inflammatory potential. Antioxidants. 2020;9(5):455.","journal-title":"Antioxidants"},{"issue":"2","key":"2936_CR151","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3987\/COM-00-S(I)89","volume":"54","author":"J Kubisch","year":"2001","unstructured":"Kubisch J, Sedmera P, Halada P. Chemoenzymatic preparation of oligoglycosides of silybin, the flavonolignan from Silybum marianum. Heterocycles. 2001;54(2):901\u201315.","journal-title":"Heterocycles"},{"key":"2936_CR152","doi-asserted-by":"crossref","unstructured":"Skottov\u00e1 N, \u0160vagera Z, Vecera R, Urb\u00e1nek K, Jegorov A, Sim\u00e1nek V. Pharmacokinetic study of iodine-labeled silibinins in rat. Pharmacol Res. 2001; 44(3):247\u201353.","DOI":"10.1006\/phrs.2001.0854"},{"issue":"1\u20132","key":"2936_CR153","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tox.2005.06.020","volume":"215","author":"M Pl\u00edskov\u00e1","year":"2005","unstructured":"Pl\u00edskov\u00e1 M, Vondr\u00e1cek J, Kren V, Gaz\u00e1k R, Sedmera P, Walterov\u00e1 D, Psotov\u00e1 J, Sim\u00e1nek V, Machala M. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation. Toxicology. 2005;215(1\u20132):80\u20139.","journal-title":"Toxicology"},{"key":"2936_CR154","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.fitote.2017.04.012","volume":"119","author":"L Roubalov\u00e1","year":"2017","unstructured":"Roubalov\u00e1 L, Dinkova-Kostova AT, Biedermann D, K\u0159en V, Ulrichov\u00e1 J, Vrba J. Flavonolignan 2,3-dehydrosilydianin activates Nrf2 and upregulates NAD(P)H:quinone oxidoreductase 1 in Hepa1c1c7 cells. Fitoterapia. 2017;119:115\u201320.","journal-title":"Fitoterapia"},{"key":"2936_CR155","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.freeradbiomed.2015.11.014","volume":"90","author":"M Pyszkov\u00e1","year":"2016","unstructured":"Pyszkov\u00e1 M, Biler M, Biedermann D, Valentov\u00e1 K, Kuzma M, Vrba J, Ulrichov\u00e1 J, Sokolov\u00e1 R, Mojovi\u0107 M, Popovi\u0107-Bijeli\u0107 A, et al. Flavonolignan 2,3-dehydroderivatives: preparation, antiradical and cytoprotective activity. Free Radical Biol Med. 2016;90:114\u201325.","journal-title":"Free Radical Biol Med"},{"issue":"23","key":"2936_CR156","doi-asserted-by":"publisher","first-page":"7732","DOI":"10.1021\/jm900735p","volume":"52","author":"LX Yang","year":"2009","unstructured":"Yang LX, Huang KX, Li HB, Gong JX, Wang F, Feng YB, Tao QF, Wu YH, Li XK, Wu XM, et al. Design, synthesis, and examination of neuron protective properties of alkenylated and amidated dehydro-silybin derivatives. J Med Chem. 2009;52(23):7732\u201352.","journal-title":"J Med Chem"},{"issue":"6","key":"2936_CR157","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00403-019-01928-7","volume":"311","author":"A Rajnochov\u00e1 Svobodov\u00e1","year":"2019","unstructured":"Rajnochov\u00e1 Svobodov\u00e1 A, Gabrielov\u00e1 E, Ulrichov\u00e1 J, Z\u00e1le\u0161\u00e1k B, Biedermann D, Vost\u00e1lov\u00e1 J. A pilot study of the UVA-photoprotective potential of dehydrosilybin, isosilybin, silychristin, and silydianin on human dermal fibroblasts. Arch Dermatol Res. 2019;311(6):477\u201390.","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"2936_CR158","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.3390\/molecules23102594","volume":"23","author":"S Drouet","year":"2018","unstructured":"Drouet S, Doussot J, Garros L, Mathiron D, Bassard S, Favre-R\u00e9guillon A, Molini\u00e9 R, Lain\u00e9 \u00c9, Hano C. Selective synthesis of 3-O-palmitoyl-silybin, a new-to-nature flavonolignan with increased protective action against oxidative damages in lipophilic media. Molecules. 2018;23(10):2594.","journal-title":"Molecules"},{"issue":"11","key":"2936_CR159","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3390\/molecules24112155","volume":"24","author":"A Di Costanzo","year":"2019","unstructured":"Di Costanzo A, Angelico R. Formulation strategies for enhancing the bioavailability of silymarin: the state of the art. Molecules. 2019;24(11):2155.","journal-title":"Molecules"},{"issue":"2","key":"2936_CR160","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1166\/jbn.2007.024","volume":"3","author":"J He","year":"2007","unstructured":"He J, Hou S, Lu W, Zhu L, Feng J. Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J Biomed Nanotechnol. 2007;3(2):195\u2013202.","journal-title":"J Biomed Nanotechnol"},{"issue":"1","key":"2936_CR161","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jpha.2018.09.003","volume":"9","author":"AM Yousaf","year":"2019","unstructured":"Yousaf AM, Malik UR, Shahzad Y, Mahmood T, Hussain T. Silymarin-laden PVP-PEG polymeric composite for enhanced aqueous solubility and dissolution rate: preparation and in vitro characterization. J Pharmaceut Anal. 2019;9(1):34\u20139.","journal-title":"J Pharmaceut Anal"},{"key":"2936_CR162","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ijpharm.2019.03.064","volume":"563","author":"AH Ibrahim","year":"2019","unstructured":"Ibrahim AH, Rosqvist E, Sm\u00e5tt JH, Ibrahim HM, Ismael HR, Afouna MI, Samy AM, Rosenholm JM. Formulation and optimization of lyophilized nanosuspension tablets to improve the physicochemical properties and provide immediate release of silymarin. Int J Pharm. 2019;563:217\u201327.","journal-title":"Int J Pharm"},{"issue":"3","key":"2936_CR163","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajps.2014.12.001","volume":"10","author":"G Yang","year":"2015","unstructured":"Yang G, Zhao Y, Feng N, Zhang Y, Liu Y, Dang B. Improved dissolution and bioavailability of silymarin delivered by a solid dispersion prepared using supercritical fluids. Asian J Pharm Sci. 2015;10(3):194\u2013202.","journal-title":"Asian J Pharm Sci"},{"issue":"5","key":"2936_CR164","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s13346-019-00640-3","volume":"9","author":"SS Nasr","year":"2019","unstructured":"Nasr SS, Nasra MMA, Hazzah HA, Abdallah OY. Mesoporous silica nanoparticles, a safe option for silymarin delivery: preparation, characterization, and in vivo evaluation. Drug Deliv Transl Res. 2019;9(5):968\u201379.","journal-title":"Drug Deliv Transl Res"},{"key":"2936_CR165","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jddst.2017.05.019","volume":"40","author":"A Nagi","year":"2017","unstructured":"Nagi A, Iqbal B, Kumar S, Sharma S, Ali J, Baboota S. Quality by design based silymarin nanoemulsion for enhancement of oral bioavailability. J Drug Del Sci Technol. 2017;40:35\u201344.","journal-title":"J Drug Del Sci Technol"},{"key":"2936_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrgentox.2015.08.006","volume":"792","author":"M Adhikari","year":"2015","unstructured":"Adhikari M, Arora R. Nano-silymarin provides protection against \u03b3-radiation-induced oxidative stress in cultured human embryonic kidney cells. Mutat Res Genet Toxicol Environ Mutagen. 2015;792:1\u201311.","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"issue":"10","key":"2936_CR167","first-page":"1446","volume":"24","author":"M Azadpour","year":"2021","unstructured":"Azadpour M, Farajollahi MM, Dariushnejad H, Varzi AM, Varezardi A, Barati M. Effects of synthetic silymarin-PLGA nanoparticles on M2 polarization and inflammatory cytokines in LPS-treated murine peritoneal macrophages. Iran J Basic Med Sci. 2021;24(10):1446\u201354.","journal-title":"Iran J Basic Med Sci"},{"issue":"1","key":"2936_CR168","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medicina54010001","volume":"54","author":"M Mombeini","year":"2018","unstructured":"Mombeini M, Saki G, Khorsandi L, Bavarsad N. Effects of silymarin-loaded nanoparticles on HT-29 human colon cancer cells. Medicina. 2018;54(1):1.","journal-title":"Medicina"},{"issue":"15","key":"2936_CR169","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.2217\/nnm-2017-0394","volume":"13","author":"M El-Far","year":"2018","unstructured":"El-Far M, Salah N, Essam A, Abd El-Azim AO, El-Sherbiny IM. Silymarin nanoformulation as potential anticancer agent in experimental Ehrlich ascites carcinoma-bearing animals. Nanomedicine. 2018;13(15):1858\u201365.","journal-title":"Nanomedicine"},{"key":"2936_CR170","doi-asserted-by":"publisher","first-page":"100253","DOI":"10.1016\/j.phanu.2021.100253","volume":"15","author":"S Hosseini","year":"2021","unstructured":"Hosseini S, Rezaei S, Moghaddam MRN, Elyasi S, Karimi G. Evaluation of oral nano-silymarin formulation efficacy on prevention of radiotherapy induced mucositis: a randomized, double-blinded, placebo-controlled clinical trial. PharmaNutrition. 2021;15:100253.","journal-title":"PharmaNutrition"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-02936-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-023-02936-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-02936-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T04:04:04Z","timestamp":1729397044000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-023-02936-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,10]]},"references-count":170,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2936"],"URL":"https:\/\/doi.org\/10.1186\/s12935-023-02936-4","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,10]]},"assertion":[{"value":"17 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}